PRAME like-3 Inhibitors
PRAME like-3 inhibitors encompass a diverse array of chemical compounds that target various signaling pathways and cellular processes to reduce the functional activity of this protein. For example, Palbociclib, a CDK4/6 inhibitor, could potentially impair the involvement of PRAME like-3 in cell cycle progression by arresting the cycle at a point where PRAME like-3 is operational. Similarly, LY294002 and Rapamycin, inhibitors of PI3K and mTOR respectively, may diminish PRAME like-3's role in growth and survival signaling by obstructing these pathways. U0126, which targets the MAPK/ERK pathway, and Gefitinib, an EGFR inhibitor, can also indirectly mitigate PRAME like-3's activity by damping the proliferative signals that may be modulated by PRAME like-3. The functional activity of PRAME like-3 could be further influenced by Trichostatin A and Vorinostat, both histone deacetylase inhibitors that alter gene expression, possibly affecting genes regulated by PRAME like-3.
Moreover, Bortezomib and MG132, as proteasome inhibitors, have the potential to modulate the protein turnover and therefore the activity of PRAME like-3 if its regulation involves ubiquitination pathways. In the case of SB431542, an inhibitor of the TGF-β receptor, the inhibition could lead to a decrease in PRAME like-3 activity by impeding differentiation signals where PRAME like-3 might play a role. Nutlin-3's stabilization of p53 through MDM2 antagonism could also result in a reduced function of PRAME like-3, assuming that PRAME like-3 is active in a p53-inhibited context. Furthermore, Imatinib's inhibition of tyrosine kinases like BCR-ABL, c-Kit, and PDGFR suggests a potential decline in PRAME like-3 activity if it is associated with these kinases' signaling pathways. The inhibitors' mechanisms of action collectively reveal a strategic blockade at various regulatory points within the cellular machinery, all of which could converge to attenuate PRAME like-3's functional activity, highlighting the complex interplay between PRAME like-3 and multiple cellular signaling cascades.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
A CDK4/6 inhibitor that disrupts cell cycle progression. Since PRAME like-3 is potentially involved in cell cycle control, inhibiting CDK4/6 could reduce the functional activity of PRAME like-3 by halting cell cycle progression where PRAME like-3 might be critical. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
A histone deacetylase inhibitor that leads to chromatin remodeling. It could indirectly inhibit PRAME like-3 by altering gene expression patterns, including those genes that are regulated by or are dependent on PRAME like-3 function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that prevents the activation of AKT, thereby impacting signaling pathways that PRAME like-3 could be involved in, especially if PRAME like-3 is linked to growth or survival signals. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
An inhibitor of the TGF-β receptor which could impact cell differentiation pathways. If PRAME like-3 is involved in differentiation processes, this inhibitor could decrease its functional activity by blocking the pathway. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that can prevent the degradation of proteins involved in cell cycle control. If PRAME like-3 is stabilized by the ubiquitin-proteasome system, inhibition could lead to decreased function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can suppress cell growth and proliferation. If PRAME like-3 is part of the mTOR signaling pathway, inhibiting mTOR could decrease PRAME like-3 functional activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A MEK inhibitor that blocks the MAPK/ERK pathway, which is often involved in cell proliferation and survival. Inhibition of this pathway could indirectly decrease the functional activity of PRAME like-3 if it is part of or regulated by this pathway. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
An MDM2 antagonist that stabilizes p53, leading to cell cycle arrest or apoptosis. If the function of PRAME like-3 is dependent on a p53-suppressed environment, its activity could be indirectly decreased by Nutlin-3. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
A tyrosine kinase inhibitor that targets BCR-ABL, c-Kit, and PDGFR. If PRAME like-3 is involved in signaling pathways downstream of these kinases, Imatinib could decrease its functional activity. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Another histone deacetylase inhibitor that leads to changes in gene expression. If PRAME like-3 is regulated by acetylation status, Vorinostat could decrease its function by altering histone acetylation and subsequent gene expression. | ||||||